Regeneron

Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion.

Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the bro

In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments wo

A 4.89% slide to $729.05 takes roughly $3.6 billion off the biotech

Regeneron's trevogrumab halved muscle loss by half when taken alongside semaglutide in an obesity trial. Read more.

Sanofi (SNY) stock gained after announcing an $8 billion deal with Regeneron to develop four new inflammatory disease drugs while settling prior disputes.

The healthcare company will release its third-quarter results next month.

They could both outperform the market over the medium term, but one appears to have a clear edge.